Overview Dividends

(VRTX) Vertex Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92532F1003

Cystic Fibrosis, Sickle Cell, Beta Thalassemia, Acute Pain, Kidney Disease

VRTX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 9.29%
EPS Trend (3Y Correlation): 0.7%

VRTX Revenue

Revenue Growth (3Y CAGR): 11.11%
Revenue Trend (3Y Correlation): 97.3%

Risk via 10d forecast
Volatility	26.1%
Value at Risk 5%th	41.3%

Reward
Sharpe Ratio	-0.43
Alpha	-22.90

Character
Hurst Exponent	0.387
Beta	0.322

Drawdowns 3y
Max DD	29.07%
Mean DD	7.51%

Description: VRTX Vertex Pharmaceuticals September 25, 2025

Vertex Pharmaceuticals (NASDAQ:VRTX) is a Boston-based biotech focused on cystic fibrosis (CF) therapeutics, commercializing a suite of CFTR modulators-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO-that together address over 90 % of the U.S. CF patient population across age groups.

The company’s pipeline extends beyond CF to rare-disease and metabolic indications: CASGEVY for sickle-cell disease and transfusion-dependent β-thalassemia (Phase III pending FDA review), JOURNAVX for acute adult pain, VX-522 (CFTR mRNA therapy, Phase 1/2), inaxaplin for APOL1-mediated kidney disease (Phase 2), VX-880/VX-264 for type 1 diabetes, VX-670 for myotonic dystrophy type 1, and VX-407 for autosomal dominant polycystic kidney disease.

Vertex distributes its products through specialty pharmacies, specialty distributors, retail pharmacies, hospitals, and clinics in the United States, and maintains strategic collaborations with CRISPR Therapeutics, Moderna, and Entrada Therapeutics to accelerate gene-editing and mRNA platforms.

Key financial and market drivers: FY 2023 revenue reached approximately $9.0 billion, with ~71 % derived from the CF franchise; the company held a cash and short-term investment balance of $5.5 billion, providing runway for pipeline expansion; the global CF market is projected to grow at a CAGR of ~7 % through 2030, supporting continued demand for Vertex’s modulators.

For a deeper dive into Vertex’s valuation metrics and scenario analysis, the ValueRay platform offers a useful toolkit.

VRTX Stock Overview

Market Cap in USD	103,890m
Sub-Industry	Biotechnology
IPO / Inception	1991-07-24
Return 12m vs S&P 500	-27.1%
Analyst Rating	3.85 of 5

VRTX Dividends

Currently no dividends paid

VRTX Growth Ratios

CAGR	11.35%
CAGR/Max DD Calmar Ratio	0.39
CAGR/Mean DD Pain Ratio	1.51
Current Volume	1494.4k
Average Volume	1314.4k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (3.68b TTM) > 0 and > 6% of Revenue (6% = 703.4m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA 19.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 51.98% (prev 54.89%; Δ -2.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 3.72b > Net Income 3.68b (YES >=105%, WARN >=100%)

Net Debt (-3.10b) to EBITDA (4.61b) ratio: -0.67 <= 3.0 (WARN <= 3.5)

Current Ratio 2.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (257.6m) change vs 12m ago -1.30% (target <= -2.0% for YES)

Gross Margin 86.28% (prev 86.11%; Δ 0.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.78% (prev 47.76%; Δ 2.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 246.7 (EBITDA TTM 4.61b / Interest Expense TTM 12.8m) >= 6 (WARN >= 3)

Altman Z'' 5.84

(A) 0.25 = (Total Current Assets 10.57b - Total Current Liabilities 4.48b) / Total Assets 24.86b

(B) 0.50 = Retained Earnings (Balance) 12.37b / Total Assets 24.86b

(D) 1.63 = Book Value of Equity 12.31b / Total Liabilities 7.54b

Total Rating: 5.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 85.81

1. Piotroski 7.0pt = 2.0

2. FCF Yield 3.36% = 1.68

3. FCF Margin 28.47% = 7.12

4. Debt/Equity 0.11 = 2.49

5. Debt/Ebitda -0.67 = 2.50

6. ROIC - WACC (= 8.69)% = 10.87

7. RoE 21.81% = 1.82

8. Rev. Trend 97.33% = 7.30

9. EPS Trend 0.66% = 0.03

What is the price of VRTX shares?

As of November 11, 2025, the stock is trading at USD 421.20 with a total of 1,494,401 shares traded.
Over the past week, the price has changed by -1.13%, over one month by +3.29%, over three months by +12.48% and over the past year by -16.05%.

Is Vertex Pharmaceuticals a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Vertex Pharmaceuticals (NASDAQ:VRTX) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 85.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRTX is around 406.69 USD . This means that VRTX is currently overvalued and has a potential downside of -3.44%.

Is VRTX a buy, sell or hold?

Vertex Pharmaceuticals has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy VRTX.

Strong Buy: 14
Buy: 4
Hold: 14
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the VRTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	479.9	13.9%
Analysts Target Price	479.9	13.9%
ValueRay Target Price	449.3	6.7%

VRTX Fundamental Data Overview November 11, 2025

Market Cap USD = 103.89b (103.89b USD * 1.0 USD.USD)
P/E Trailing = 28.8156
P/E Forward = 20.9205
P/S = 8.8619
P/B = 6.1032
P/EG = 0.5801
Beta = 0.322
Revenue TTM = 11.72b USD
EBIT TTM = 3.16b USD
EBITDA TTM = 4.61b USD
Long Term Debt = 1.75b USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 92.3m USD (from shortTermDebt, last fiscal year)
Debt = 1.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.10b USD (from netDebt column, last quarter)
Enterprise Value = 99.44b USD (103.89b + Debt 1.83b - CCE 6.29b)
Interest Coverage Ratio = 246.7 (Ebit TTM 3.16b / Interest Expense TTM 12.8m)
FCF Yield = 3.36% (FCF TTM 3.34b / Enterprise Value 99.44b)
FCF Margin = 28.47% (FCF TTM 3.34b / Revenue TTM 11.72b)
Net Margin = 31.35% (Net Income TTM 3.68b / Revenue TTM 11.72b)
Gross Margin = 86.28% ((Revenue TTM 11.72b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 86.52% (prev 86.25%)
Tobins Q-Ratio = 4.00 (Enterprise Value 99.44b / Total Assets 24.86b)
Interest Expense / Debt = 0.18% (Interest Expense 3.30m / Debt 1.83b)
Taxrate = 16.62% (215.9m / 1.30b)
NOPAT = 2.63b (EBIT 3.16b * (1 - 16.62%))
Current Ratio = 2.36 (Total Current Assets 10.57b / Total Current Liabilities 4.48b)
Debt / Equity = 0.11 (Debt 1.83b / totalStockholderEquity, last quarter 17.32b)
Debt / EBITDA = -0.67 (Net Debt -3.10b / EBITDA 4.61b)
Debt / FCF = -0.93 (Net Debt -3.10b / FCF TTM 3.34b)
Total Stockholder Equity = 16.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.78% (Net Income 3.68b / Total Assets 24.86b)
RoE = 21.81% (Net Income TTM 3.68b / Total Stockholder Equity 16.85b)
RoCE = 16.98% (EBIT 3.16b / Capital Employed (Equity 16.85b + L.T.Debt 1.75b))
RoIC = 15.77% (NOPAT 2.63b / Invested Capital 16.69b)
WACC = 7.08% (E(103.89b)/V(105.73b) * Re(7.20%) + D(1.83b)/V(105.73b) * Rd(0.18%) * (1-Tc(0.17)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.63%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈3.34b ; Y1≈2.19b ; Y5≈1.00b
Fair Price DCF = 77.62 (DCF Value 19.69b / Shares Outstanding 253.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 0.66 | EPS CAGR: 9.29% | SUE: 0.03 | # QB: 0
Revenue Correlation: 97.33 | Revenue CAGR: 11.11% | SUE: 0.23 | # QB: 0

Additional Sources for VRTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle